CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age.
To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar’s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases.
EDITOR’S NOTE: Dr. Hanadie Yousef of Juvena Therapeutics discusses the secretome, the signaling system of cells that affect the behavior of other cells. The secretome of embryonic stem cells encourages other cells to grow and develop, providing a rejuvenative effect. Isolating these proteins and introducing them into aging tissues is the basis for a potential suite of therapies for age-related diseases.